Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancerShikhar Sharma, Meghan Hattarki, Chi‐Yeh Chung et al.|Cell chemical biology|2023Cited by 72
Genetic Variation in Type 1 Diabetes Reconfigures the 3D Chromatin Organization of T Cells and Alters Gene ExpressionMaria Fasolino, Golnaz Vahedi, Eric F. Joyce et al.|Immunity|2020Cited by 55
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemiaShellaina J.V. Gordon, Mark A. Dawson, Florian Perner et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 5
Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamideShikhar Sharma, Pei‐Pei Kung, Jelena Petrovic et al.|Cancer Research|2025Cited by 0
Abstract C029: PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancerShikhar Sharma, Thomas A. Paul, Paul Richardson et al.|Molecular Cancer Therapeutics|2025Cited by 0